Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | BPTF | Q12830 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201860 | 0.89 | MKNK2 (0.37) | F10HDAC1PDE1BMKNK2TYK2 | |
| SCHEMBL608744 | 0.87 | F10 (0.45) | F10PDE1BBPTFPDCD1CD274 | |
| SCHEMBL10255882 | 0.78 | BTK (0.36) | PDE1BMKNK2TYK2JAK2JAK1 | |
| SCHEMBL10255979 | 0.77 | BTK (0.40) | F10TYK2JAK2JAK1JAK3 | |
| SCHEMBL611354 | 0.76 | MAPK1 (0.42) | SMN1; SMN2HCAR3TYK2JAK2JAK1 | |
| SCHEMBL28382231 | 0.75 | BRAF (0.34) | MKNK2TYK2JAK2JAK1JAK3 | |
| SCHEMBL10255810 | 0.75 | BRAF (0.32) | TYK2JAK2JAK1JAK3BPTF | |
| SCHEMBL609443 | 0.75 | HCAR3 (0.48) | HCAR3 | |
| SCHEMBL610722 | 0.72 | AXL (0.41) | PDE1BPDCD1CD274 | |
| SCHEMBL15101753 | 0.72 | PKM (0.47) | MEN1KMT2ASMN1; SMN2HCAR3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2603500-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2014-11-19 | — | — | EP | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2603500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | F10 1411/4885HDAC1 1613/4885HDAC6 1503/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | F10 1411/4885HDAC1 1613/4885HDAC6 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.